Capping Medicare beneficiaries’ monthly insulin out-of-pocket costs at $35 was associated with steep reductions in spending ...

Steven Kheloussi, PharmD, explores how smarter clinical tools, multidisciplinary teams, and better care coordination can ...

ATTAIN demonstrated placebo-adjusted weight reductions of roughly 9–11 percentage points at 72 weeks, with 27.3 lb (12.4%) ...

Federal pharmacy benefit manager transparency reforms must contend with concentrated pharmaceutical markets that lack ...

Building on insights from last year, experts across sessions at the 2026 American Academy of Dermatology (AAD) Annual Meeting ...

HB 4965 permits switching to an alternative medically appropriate treatment of equal or lesser value after initial approval, ...

Collapsing the very-low-risk category reflects broader acceptance of active surveillance for Gleason 6 disease, while PARP ...

From teledermatology billing to rural outreach and transplant advances, new studies and presentations reveal shifts in access ...

Price variation does not just occur across markets and services; it also emerges between networks and providers.

“Interestingly, BIRC5 and MCL-1 have both been reported to be over-expressed and strongly correlated with progression and ...

Lauren Madigan, MD, shares open-label extension results demonstrating sustained improvements with avapritinib in patients ...

The CDC announced on April 1 that they would be downsizing their operations, leading to the pause of diagnostic testing for mpox, rabies, and more than 2 dozen other infectious diseases. 1 The CDC has ...